A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)

NCT00000968 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: gp160 Vaccine (Immuno-AG)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]